Drug Trial Radar · NCT01235546
Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection
Last checked: Nov 19, 2026Latest source record: Jul 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,013
Actual
Start
May 2011
Primary completion
Dec 2015
Study completion Dec 2015
Sponsor
- Lead sponsor
- Alan TitaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); University of Texas; University of North Carolina; Mission Hospital; Ochsner Health System; The University of Texas Health Science Center, Houston; Columbia University; University of Utah; University of Mississippi Medical Center
- First posted
- Nov 5, 2010
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- Female only, from 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Cesarean Section Optimal Antibiotic Prophylaxis (C/SOAP) study is a large pragmatic multi-center randomized clinical trial designed to evaluate the comparative effectiveness and safety of azithromycin-based extended-spectrum antibiotic prophylaxis (azithromycin plus standard narrow-spectrum cephalosporin) relative to standard single-agent cephalosporin (preferably prior to surgical incision) to prevent post-cesarean infection. Hypothesis: Compared to narrow-spectrum prophylaxis (i.e. cefazolin alone, or clindamycin if cephalosporin allergy) prior to surgical incision, the addition of extended-spectrum prophylaxis (azithromycin + cefazolin) reduces the incidence of post-cesarean infection.
Conditions
- Endometritis
- Wound Infection
- Abscess
- Surgical Site Infection
Interventions
Azithromycin and standard of careDrug
500 mg in 250 cc normal saline 1 time dose plus standard of care (cephazolin or clindamycin)
Placebo and standard of careDrug
250 cc normal saline, plus standard of care (cephazolin or clindamycin)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants With Endometritis and/or Wound Infection and/or Other Post-cesarean Infections (Occurring Within 6 Weeks of Delivery)Time frame: Up to 6 weeks after delivery
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Ochsner Clinic Foundation
New Orleans, Louisiana
University of Mississippi Medical Center
Jackson, Mississippi
Columbia University
New York, New York
Mission Hospital
Asheville, North Carolina
University of North Carolina
Chapel Hill, North Carolina
University of Texas Medical Branch
Galveston, Texas
University of Texas Health Science Center at Houston
Houston, Texas
University of Utah
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.